Upgrade to SI Premium - Free Trial

Needham & Company Reiterates Buy Following Imperva's (IMPV) 4Q Beat and Raise

February 4, 2016 6:45 AM
Needham & Company maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $56.00 (from $88.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles